Adalimumab vs placebo
Failure to maintain endoscopic remission · Participants with Crohn's disease in remission
Adalimumab probably leads to lower failure to maintain endoscopic remission compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.74 [0.63, 0.87]1 study · 129 participantsModerate